Pharma Focus Europe

Ribo and Boehringer Ingelheim Collaborate to Create Innovative Treatments for Individuals With Liver Diseases

Thursday, January 04, 2024

Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) have jointly announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). This partnership brings together Ribo's significant experience in the discovery and clinical development of small interfering RNA (siRNA) therapeutics with Boehringer's dedication to improving the lives of people living with cardiovascular, renal, and metabolic diseases (CRM).

NASH, an inflammatory liver condition resulting from fat accumulation in the liver, affects over 440 million people worldwide. Over time, NASH can lead to the formation of scar tissue, often resulting in severe complications such as liver cirrhosis, liver failure, or liver cancer. Currently, there are no approved medications for NASH, highlighting the urgent need for effective treatment options that can impede NASH progression and sustain or restore liver function.

Ribo's advanced RIBO-GalSTAR™ platform allows for the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes by silencing their messenger RNAs (mRNAs). This innovative approach has the potential to address previously inaccessible drug targets, offering new possibilities for treating diseases.

"We are excited to collaborate with Ribo's scientists to develop groundbreaking medicines for NASH patients," stated Søren Tullin, Ph.D., Senior Vice President and Global Head of Cardiometabolic Diseases Research at Boehringer Ingelheim. "This partnership is part of our commitment to collaborating globally to tackle the interconnected nature of CRM diseases, aiming to develop innovative medicines for holistic health benefits in patients."

Zicai Liang, CEO of Ribo Life Sciences, expressed enthusiasm, saying, "This collaboration is a significant endorsement of the years of investment and scientific discovery embedded in Ribo's platform. We are pleased to work with Boehringer Ingelheim to create new solutions for individuals living with NASH."

Li-Ming Gan, CEO of Ribocure, added, "We anticipate a productive collaboration with Boehringer Ingelheim, leveraging their unparalleled experience and understanding of CRM conditions to continue delivering breakthrough medicines in this field."

As per the agreement terms, Ribo will receive an upfront payment. The collaboration includes success-based milestones for clinical, regulatory, and commercial achievements, along with tiered royalties. The overall deal value surpasses USD 2 billion in this multi-target collaboration.

 

 

Source: prnewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva